|
Pharmaceutical R&D Productivity Crisis:
The End of an Old Era or the Beginning of a New One?
Date: Friday, May 13, 2005
- Registration and breakfast: 8:30 AM to 9:15 AM
- Morning session: 9:15 AM to11:30 AM
- Lunch: 11:30 AM to 1:00 PM
- Afternoon session: 1:00 PM to 2:00 PM
- Panel discussion: 2:00 PM to 3:00 PM
- Network reception: 3:00 PM to 4:30 PM
Place:
Bridgewater Manor,
1251 Route 202/206
Bridgewater, New Jersey 08807
Phone: (908) 658-3000
Driving directions:(http://www.bridgewatermanor.com)
Registration fees:
$90 (regular), $20 (student and postdoc)
Registration Online: www.sapaweb.org
Registration On Site: Available on Friday (cash or check)
Why Should You Attend the Symposium?
This is the symposium just designed for you:
- To keep updated about the industry R&D trend
- To adapt yourself for changes ahead of the curve
- To learn what "hot" projects you might want to get on board in the company
- To be empowered to stand out with leadership thinking at your project team meetings
- To come away with new ideas to improve your technical skills and advance your career
- To network with your industry peers
Program:
A Future Outlook of Chemical Enterprise:
A Pharmaceutical Industry Perspective
Dr. Magid Abou-Gharbia
Sr. Vice President and Head, Chemical and Screening Sciences, Wyeth
A Case Study of Drug Development:
Therapeutic Target in the Leukotriene Pathway
Dr. Jilly Evans
Director, Department of Cardiovascular Diseases, Merck
The Declining Pharmaceutical R&D Productivity:
Role of Clinical
Pharmacology in a Changing Environment
Dr. Jean-Michel Gries
U.S. Head, Clinical Pharmacology, Hoffmann-La Roche
Enhancing the Efficiency of Medicinal Chemistry
Dr. Donald Kyle
Executive Director, Computational, Combinatorial & Medicinal Chemistry, Purdue Pharma
Bridging Operational and Strategic Metrics
Dr. Gen Li
Head of Productivity, Development Operations, Pfizer
A Look at Pharmaceutical Industry's Focus on Addressing Candidate Attrition Due to ADMET
Dr. Yuezhong Shu
Associate Director, Pharmaceutical Candidate Optimization, Bristol-Myers Squibb
Additional Discussion Panelist
Dr. Lian-Feng Huang
Head of Pharmaceutical Sciences, Johnson & Johnson Pharmaceutical Research & Development
Organizer Committee:
Dr. Mike Liu, (Co-Chair), Purdue Pharma
Dr. George Xiao (Co-Chair), Schering-Plough Research Institute
Ms. Helena Feng (Treasurer), Wyeth
Dr. John Hu (SAPA President), US Pharmacopoeia
Dr. Yusheng Wu (SAPA President Elect), Schering-Plough Research Institute
Dr. Charles Wang, Johnson & Johnson
Symposium Theme:
The obvious slowdown in the pharma productivity has invoked many thought leaders in both regulatory and industrial fields. After FDA published the white paper on the critical path analysis during the drug development, there are tremendous efforts to accelerate the drug development processes in both pharma industry and academia. 2005 SAPA R&D Symposium will discuss some of the latest advances in the critical paths highlighted in the FDA white paper.
The pharmaceutical industry is under unprecedented pressure to sustain its growth: patent expiration for dozens of major drugs, fewer new drug approvals, drug recalls and stronger warning labels, rising price pressure, and cheap drug reimportation threat. At the core of all these challenges is an ongoing R&D productivity crisis: while annual total R&D investment has more than doubled in the past decade, the trend of NME approvals per year has been moving downward. It is shocking to note that in 2005 three of top five big pharmas had no NME approvals from their own research pipelines.
The industry is at a crossroads, and needs an under-the-hood check-up of its R&D engine before moving on a growth track again. At the Symposium, we have invited a panel of industry R&D experts across the disciplines to review what we have achieved, where we are, and possible paths to our future. Importantly, we will open up a forum with you, players in various parts of drug discovery and development, to discuss together:
Big-picture view of the R&D productivity crisis:
— Is the current pharmaceutical model broken? Or would big pharmas become giant marketing machines and outsource most their R&D?
— Is the industry deemed for fundamental changes in drug discovery and development?
— What short-term and long-term solutions could we explore to improve R&D productivity?
— A few big pharmas return to hire their Chief Scientific Officer directly out of academia. Novartis' new research center in Boston had one third of the new hires coming directly from the academic labs, an unusually high figure. What's behind this "back to basic science" thinking?
It is interesting to note that ongoing discussions of R&D productivity generally chase the "quantity" side of the equation, i.e. to make existing activity more efficient. However, currently only 20% of approved NMEs are considered innovative drugs. We cannot address the market demand for innovative life-saving and more effective drugs until we have a better handle on "quality".
— How much "quantative" productivity could we increase through cost savings from outsourcing and operation efficiency improvement?
— More significantly, what should we do to improve "qualitative" productivity?
In the past decade, a parade of enabling technologies has promised to transform pharmaceutical R&D:
— Have these technologies, e.g. high throughput screening and combinatorial chemistry, delivered their original promises? Why or why not?
— How much could new tools, like genomics, proteomics, predictive ADMET, bioinformatics, and systems biology, offer to improve R&D productivity?
If you want to submit your questions to the Panel Discussion in advance, please email Dr. Mike Liu at ml39@yahoo.com
|
